Trial · NCT00667394
Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors
NCT00667394, Phase 2, Completed, National Cancer Institute (NCI); results first posted 2012-08-31
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors. Trials, record NCT00667394. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00667394
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors
- NCT number
- NCT00667394
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 42 participants, actual
- Lead sponsor
- National Cancer Institute (NCI)
- Conditions
- Glioblastoma, Gliosarcoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Mixed Oligoastrocytoma
- Interventions
- Bevacizumab, MLN-518 (Tandutinib), Quality-of-life assessment
- First posted
- 2008-04-28
- Last updated
- 2015-11-05
- Results first posted
- 2012-08-31
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression-free Survival at 6 Months | 6 months | Percentage of participants with progression free survival at 6 months. Progression is defined as a 25% increase in the sum of all measurable lesions (or two largest lesions if too numerous) over the smallest sum observed (over baseline if no decrease), clear worsening of any evaluable disease, appearance of any new lesion/site, or failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer). |
| Secondary | Number of Participants With Adverse Events | 45 months | Here is the number of participants with adverse events. For the detailed list of adverse events see the adverse event module. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Progression-free Survival at 6 Months | 6 months | Percentage of participants | MEDIAN | |
| SECONDARY | Number of Participants With Adverse Events | 45 months | Participants | NUMBER |
Source ClinicalTrials.gov
Results by group3
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Progression-free Survival at 6 Months | Tandutinib & Bevacizumab in GBM Patients | 23 | 95% Confidence Interval 12 to 37 | Percentage of participants | |
| Number of Participants With Adverse Events | Tandutinib & Bevacizumab in GBM Patients | 40 | Participants | ||
| Number of Participants With Adverse Events | Tandutinib & Bevacizumab in AG Patients | 1 | Participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Tandutinib & Bevacizumab in GBM Patients | 41 | |
| Overall Study | STARTED | Tandutinib & Bevacizumab in AG Patients | 1 | |
| Overall Study | COMPLETED | Tandutinib & Bevacizumab in GBM Patients | 37 | |
| Overall Study | COMPLETED | Tandutinib & Bevacizumab in AG Patients | 1 | |
| Overall Study | NOT COMPLETED | Tandutinib & Bevacizumab in GBM Patients | 4 | |
| Overall Study | NOT COMPLETED | Tandutinib & Bevacizumab in AG Patients | 0 |
Source ClinicalTrials.gov
Adverse events186
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | ALT, SGPT (serum glutamic pyruvic transaminase) | Investigations | Tandutinib & Bevacizumab in GBM Patients | 4 | 41 | 6 |
| other | ALT, SGPT (serum glutamic pyruvic transaminase) | Investigations | Tandutinib & Bevacizumab in AG Patients | 0 | 1 | 0 |
| other | AST, SGOT(serum glutamic oxaloacetic transaminase) | Investigations | Tandutinib & Bevacizumab in GBM Patients | 16 | 41 | 26 |
| other | AST, SGOT(serum glutamic oxaloacetic transaminase) | Investigations | Tandutinib & Bevacizumab in AG Patients | 0 | 1 | 0 |
| other | Albumin, serum-low (hypoalbuminemia) | Metabolism and nutrition disorders | Tandutinib & Bevacizumab in GBM Patients | 1 | 41 | 1 |
| other | Albumin, serum-low (hypoalbuminemia) | Metabolism and nutrition disorders | Tandutinib & Bevacizumab in AG Patients | 0 | 1 | 0 |
| other | Alkaline phosphatase | Investigations | Tandutinib & Bevacizumab in GBM Patients | 6 | 41 | 7 |
| other | Alkaline phosphatase | Investigations | Tandutinib & Bevacizumab in AG Patients | 0 | 1 | 0 |
| other | Allergic reaction/hypersensitivity (including drug fever) | Immune system disorders | Tandutinib & Bevacizumab in GBM Patients | 2 | 41 | 2 |
| other | Allergic reaction/hypersensitivity (including drug fever) | Immune system disorders | Tandutinib & Bevacizumab in AG Patients | 0 | 1 | 0 |
1 to 10 of 186Source ClinicalTrials.gov
See all 186 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Tandutinib & Bevacizumab in GBM Patients | ||
| Total, all-cause mortality | Tandutinib & Bevacizumab in AG Patients | ||
| Total, other adverse events | Tandutinib & Bevacizumab in GBM Patients | 41 | 41 |
| Total, other adverse events | Tandutinib & Bevacizumab in AG Patients | 1 | 1 |
| Total, serious adverse events | Tandutinib & Bevacizumab in GBM Patients | 15 | 41 |
| Total, serious adverse events | Tandutinib & Bevacizumab in AG Patients | 0 | 1 |
Source ClinicalTrials.gov
Papers6
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Tandutinib & Bevacizumab in GBM Patients vs Tandutinib & Bevacizumab in AG Patients: Number of Participants With Adverse Events | Trial comparisons |
| Tandutinib & Bevacizumab in GBM Patients vs Tandutinib & Bevacizumab in AG Patients: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00667394
GET https://conductscience.org/api/trials/v1/NCT00667394/events?page=2